Diabetic nephropathy is one of the most important complications to diabetes mellitus, and the typical clinical course of diabetic nephropathy is early hyperfiltration followed by microalbuminuria and overt proteinuria, resulting in a progressive deterioration of glomerular filtration rate. It has been considered that a renal biopsy is unnecessary in diabetic patients with typical course. Diabetic nephropathy affects approximately 40% of patients who have had diabetes for more than 20 years, and some of them have non-diabetic renal diseases. Although non-diabetic renal diseases may be of minor importance in diabetic mellitus, the correct diagnosis by a renal biopsy is important for the patients since prognosis and treatment may vary according to the underlying cause. Therefore, non-diabetic renal diseases in diabetic patients should be considered in the following instances: 1) acute onset of renal disease, that include the onset of nephrotic range proteinuria or the development of acute renal failure of unknown origin, 2) a decline rate of glomerular filtration rate or a worsening of proteinuria outside established standard clinical courses for patients with diabetic nephropathy, 3) macroscopic hematuria and/or red cell casts, 4) clinical or biochemical evidence of a systemic disorder, 5) duration of insulin-dependent diabetes less than 5 years at onset of proteinuria or 10 years at onset of renal failure, and 6) the absence of diabetic retinopathy (1) .
The overall prevalence of non-diabetic glomerular disease in type II diabetes mellitus has been reported to range from 6 to 81% (2) (3) (4) (5) (6) (7) (8) . Based on the series described in Table 1 , 25% (range, 0 to 60) of patients with type II diabetes mellitus had only non-diabetic renal diseases, and coexistence of both diabetic glomerulosclerosis and non-diabetic renal diseases had been reported in 13% (range, 0 to 33). In nondiabetic glomerulonephritis with type II diabetes mellitus patients, IgA nephropathy (32%) is the most frequent followed by membranous nephropathy (16%), minimal change nephropathy (10%), endocapillary glomerulonephritis (9%), and crescentic glomerulonephritis (6%). Moreover, a rare case of type II diabetes mellitus complicated with triple glomerulopathy, such as diabetic glomerulosclerosis, membranous nephropathy and crescentic glomerulonephritis has been reported and cases of diabetes mellitus complicated with rapidly progressive glomerulonephritis (RPGN) are reported in the last issue (9) .
The clinical symptom of patients with crescentic glomerulonephritis is consistently RPGN, and RPGN is categorized into 3 groups: the anti-glomerular basement membrane antibodies type, the immune complexes type and the pauci-immune type. Antineutrophil cytoplasmic antibodies are frequently detected in patients of the pauci-immune type, and those strongly support the diagnosis. Although myeloperoxidase (MPO)-ANCA was reported to be positive in 38% of patients with type I diabetes mellitus but in 5.7% of healthy subjects (10), it was rarely detected in patients with type II diabetes mellitus. Only nine patients with both ANCA-associated glomerulonephritis and type II diabetic mellitus were previously reported (9, (11) (12) (13) (14) (15) (16) (17) (18) . Their mean age was 68.4 years old (range, 50-88), and the ANCA pattern was the perinuclear type in all of them ( Table 2 ). The clinical feature of one patient was Churg-Strauss syndrome (11) and renal symptoms of all patients were RPGN with or without nephrotic syndrome.
Untreated patients with Wegener's granulomatosis have a 90% mortality rate within 2 years (19) . In Japan, the 6-month survival rate of patients with MPO-ANCA-associated glomerulonephritis is 74.2% and the 6-month renal survival rate, 69.9% (20) . Thus, the prognosis of ANCA-associated glomerulonephritis is not so good. However, clinical improvement is observed with the initial cyclophosphamidecorticosteroid combination treatment in approximately 90% of patients (19) , and timely initiation of immunosuppressive treatments improves the development of the renal disease and other complications, such as pulmonary involvement. Among the previously reported nine patients with both ANCA-associated glomerulonephritis and type II diabetic mellitus, renal function of all patients with serum creatinine of less than 5 mg/dl was improved. Therefore, the correct diagnosis by a renal biopsy is important for the diabetic patients with an unusual clinical course and a suitable treatment for each patient must be promptly performed. 
